Cross-disorder risk gene CACNA1C differentially modulates susceptibility to psychiatric disorders during development and adulthood

Nina Dedic(Chugai Pharma (United States)), Jan M. Deussing(Max Planck Institute of Psychiatry), Darina Czamara(Max Planck Institute of Psychiatry), Wolfgang Wurst(German Center for Neurodegenerative Diseases), Benedikt T. Bedenk(Max Planck Institute of Psychiatry), Max L. Pöhlmann(Harvard University), Julien Dine(Weizmann Institute of Science), Carsten T. Wotjak(Boehringer Ingelheim (Germany)), Adriana Lori(Emory University), Matthias Eder(Max Planck Institute of Psychiatry), Gerhard Rammes(Max Planck Institute of Psychiatry), Mathias V. Schmidt(Essen University Hospital), Lynn M. Almli(Centers for Disease Control and Prevention), Sven Moosmang(Boehringer Ingelheim (Germany)), Divya Mehta(Max Planck Society), Alon Chen(Max Planck Institute of Psychiatry), Kerry J. Ressler(McLean Hospital), Angela Jurik(Technical University of Munich), Julia Richter(Max Planck Institute of Psychiatry), Franz Hofmann(Pharmalog (Germany)), Meriah Metzger(Max Planck Institute of Psychiatry), Jakob Hartmann(Harvard University), Klaus V. Wagner(Max Planck Institute of Psychiatry), Elisabeth B. Binder(Max Planck Institute of Psychiatry)
Molecular Psychiatry
July 11, 2017
Cited by 178


Related Papers